DAILYZ HEALTH NEWS

FDA Approves First Gene-Editing Therapy for Type 1 Diabetes, Marking Major Milestone in Cell-Based Treatment

As of mid-2026, the FDA has not approved any gene-editing therapies for type 1 diabetes, with such treatments still in preclinical stages.

A six-month trial in NEJM found hybrid closed-loop insulin pumps improved A1c and reduced severe hypoglycemia in type 1 diabetes patients.

The FDA has not approved RebiQuent for moderate to severe atopic dermatitis; current oral treatments include abrocitinib and upadacitinib.

UnitedHealth’s Change Healthcare unit suffered a ransomware attack exposing data of 4.2 million patients; a $22 million ransom was paid.

A study finds changes in two blood proteins enable over 90% accurate early detection and monitoring of aggressive glioblastoma brain cancer.

The WHO launched clinical trials for Bundibugyo virus Ebola treatments and vaccines following outbreaks in the DRC and Uganda.

A Cochrane review of six trials found PSA screening likely reduces prostate cancer deaths by about two per 1,000 men screened.

CDC confirms first U.S. human H5N1 bird flu case linked to exposure to infected dairy cattle in a Texas farm worker.

CMS proposes a 3.1% payment increase for U.S. hospitals in 2027 and expands value-based quality reporting requirements.

The FDA warns against counterfeit semaglutide injections sold online after severe adverse events linked to fake Ozempic products.